[Mechanisms of the inotropic action of nonachlazine].
It has been demonstrated clinically and experimentally that administration of nonachlazine enhances myocardial contractility because of the stimulation of beta-adrenostructures and that the initial status of the latter ones determines in many respects the drug action intensity.
D000787:Angina Pectoris / Q000188:drug therapy; D000818:Animals; D002415:Cats; D003327:Coronary Disease / Q000188:drug therapy; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D004452:Echocardiography; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects*; D009628:Nonachlazine / Q000494:pharmacology* / Q000627:therapeutic use; D009638:Norepinephrine / Q000494:pharmacology; D010640:Phenothiazines / Q000494:pharmacology*; D011433:Propranolol / Q000494:pharmacology / Q000627:therapeutic use; D012110:Reserpine / Q000627:therapeutic use; D013268:Stimulation, Chemical
D010640:Phenothiazines; D009628:Nonachlazine; D012110:Reserpine; D011433:Propranolol; D009638:Norepinephrine
O mekhanizmakh inotropnogo deĭstviia nonakhlazina.